Otero Jose Manuel sold $21K of LXEO

Otero Jose Manuel (Chief Operating Officer) sold 4,666 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.48 on 2026-07-01.

Original reporting
SEC EDGAR · Otero Jose Manuel
Published Jul 1, 2026, 10:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LXEO
Neutral
medium confidence
Mentioned
$LXEO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXEONeutralLow
01

Why it matters

A COO open-market sale is disclosed without a 10b5-1 plan; however, the transaction value is modest and does not constitute a company-level catalyst.

02

Market read

Traders may monitor for patterns of continued insider selling, but this specific disclosure is unlikely to drive material repricing on its own.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing compensation schedules; the article provides no context beyond the transaction details.

Relevance 3/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-01 (after-hours) disclosing same-day insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Lexeo Therapeutics, Inc.

Company-level read

Ticker impact

$LXEONeutralMedium confidence
Context

Lexeo Therapeutics COO Otero sold 4,666 shares at $4.48 on 2026-07-01 via an open-market Form 4 transaction.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived unless follow-on selling accelerates.

Evidence & confidence

The filing is a same-day insider sale with no 10b5-1 plan stated, but the disclosed size (~$20.9k) is small and does not indicate a corporate event.

Market effects

No sector read-through; this is a single-company insider transaction with small dollar value.

None.

None.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as discretionary selling, which some traders may view as mildly bearish despite the small size.

Key entities

  • Lexeo Therapeutics, Inc.

    Subject of the Form 4 insider sale by its COO.

  • Otero Jose Manuel

    Chief Operating Officer who sold 4,666 shares on 2026-07-01.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LXEOMedAI 8/10

Lexeo Therapeutics Stock Jumps 12% On Positive Gene Therapy Data

Lexeo Therapeutics (LXEO) stock rose 12% after positive interim results from its Phase I/II HEROIC-PKP2 study of LX2020, a gene therapy for PKP2 arrhythmogenic cardiomyopathy. The therapy reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44% in high-dose patients. The company reported a Q3 net loss of $38.3 million, up from $20.3 million last year, with R&D expenses increasing to $34.5 million.

$LXEOHighAI 9/10

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.